Abstract B163: First-in-patient study of PF-04691502, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on safety, efficacy, and pharmacology.

2011 ◽  
Author(s):  
Robert Millham ◽  
Brett Houk ◽  
Gary Borzillo ◽  
Patricia LoRusso ◽  
Lisa Marburg ◽  
...  
Keyword(s):  
Advanced Cancer ◽  
Small Molecule ◽  
Dual Inhibitor ◽  
Patient Study

Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer

2014 ◽  
Vol 32 (3) ◽  
pp. 510-517 ◽  
Author(s):  
Carolyn D. Britten ◽  
Alex A. Adjei ◽  
Robert Millham ◽  
Brett E. Houk ◽  
Gary Borzillo ◽  
...  
Keyword(s):  
Phase I ◽  
Advanced Cancer ◽  
Small Molecule ◽  
Phase I Study ◽  
Dual Inhibitor

scholarly journals First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

2015 ◽  
Vol 21 (8) ◽  
pp. 1888-1895 ◽  
Author(s):  
Geoffrey I. Shapiro ◽  
Katherine M. Bell-McGuinn ◽  
Julian R. Molina ◽  
Johanna Bendell ◽  
James Spicer ◽  
...  
Keyword(s):  
Advanced Cancer ◽  
Small Molecule ◽  
Human Study ◽  
Dual Inhibitor

scholarly journals Erratum to: Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer

2014 ◽  
Vol 32 (3) ◽  
pp. 575-575
Author(s):  
Carolyn D. Britten ◽  
Alex A. Adjei ◽  
Robert Millham ◽  
Brett E. Houk ◽  
Gary Borzillo ◽  
...  
Keyword(s):  
Phase I ◽  
Advanced Cancer ◽  
Small Molecule ◽  
Phase I Study ◽  
Dual Inhibitor

Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa

2006 ◽  
Vol 4 (7) ◽  
pp. 1502-1509 ◽  
Author(s):  
E. U. GRAEFE-MODY ◽  
U. SCHUHLY ◽  
K. RATHGEN ◽  
H. STAHLE ◽  
J. M. LEITNER ◽  
...  
Keyword(s):  
Small Molecule ◽  
Factor Xa ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Dual Inhibitor

Abstract C206:In vivoactivity of SGI‐1252, a potent, small‐molecule dual inhibitor of JAK2 and ALK2

2009 ◽  
Author(s):  
Vollmer David ◽  
Jared Bearss ◽  
Carissa Jones ◽  
Virgil McCarthy ◽  
Eric Gourley ◽  
...  
Keyword(s):  
Small Molecule ◽  
Dual Inhibitor

scholarly journals Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases

2019 ◽  
Vol 12 (2) ◽  
pp. 69 ◽  
Author(s):  
Daniel A. Rodrigues ◽  
Fernanda S. Sagrillo ◽  
Carlos A. M. Fraga
Keyword(s):  
Clinical Trials ◽  
Follicular Lymphoma ◽  
Chronic Lymphocytic Leukaemia ◽  
Drug Administration ◽  
Small Molecule ◽  
Lymphocytic Leukaemia ◽  
Food And Drug Administration ◽  
Small Lymphocytic Lymphoma ◽  
Dual Inhibitor ◽  
Systemic Therapies

Duvelisib (Copiktra®) is a dual inhibitor of phosphoinositide 3-kinases (PI3Kδ and PI3Kγ). In 2018, duvelisib was first approved by the Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) after at least two prior therapies. Duvelisib has also been approved under accelerated track for relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. In this review, we provide a series of information about duvelisib, such as the development of clinical trials for LLC/SLL and FL and the steps used for its synthesis.

Sign in / Sign up

Export Citation Format

Share Document